Oral and injectable medications for the treatment of erectile dysfunction

Current Urology Reports

Volumn 1, Issue 4, 2000, Pages 307-312

  Carson, Culley C ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Apomorphine; Erectile Dysfunction; Erectile Function; Vasoactive Intestinal Polypeptide; Yohimbine

Indexed keywords

PHENTOLAMINE; TESTOSTERONE;

HUMAN; IMPOTENCE; INJECTION; MALE; ORAL DRUG ADMINISTRATION; PENIS ERECTION; PHYSIOLOGY; REVIEW; TOPICAL DRUG ADMINISTRATION; URETHRA;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; HUMANS; IMPOTENCE; INJECTIONS; MALE; PENILE ERECTION; PHENTOLAMINE; TESTOSTERONE; URETHRA;

EID: 0034585438     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-000-0012-6     Document Type: Article

References (54)

1. Andersson KE, Wagener G: Physiology of penile erection. Physiol Rev 1995, 75:191–236.
2. Raijfer J, Aronson WJ, Bush PA, et al.: Nitric oxide as a mediator of the corpus cavernosum in response to non-cholinergic non-adrenergic neurotransmission. N Engl J Med 1992, 326:90–94. DOI: 10.1056/NEJM199201093260203
3. Holmquist F, Andersson KE, Fovaeus MN, Hedlund H: Potassium channel openers for relaxation of isolated erectile tissue from rabbit. J Urol 1990, 144:146–151.
4. Kim YC, Kim JA, Hagan PO, Carson CC: Modulation of vasoactive intestinal polypeptide (VIP) mediated relaxation by nitric oxide and prostinoids in the rabbit corpus cavernuosum. J Urol 1995, 153:807–810. DOI: 10.1016/S0022-5347(01)67727-9
5. Iwanaga T, Hanyu S, Tamaki M: VIP and other bioactive substances involved in penile erection. Bio Med Res 1992, 2:71–73.
6. Kerfoot WW, Schwartz LB, Hagen PO, Carson CC: Characterization of contracting and relaxing agents in human and rabbit corpus cavernosum. Surg Forum 1991, 42:688–689.
7. Kim SC, Ooh MM: Norepinephrine involvement in response to intracorporeal injection of papaverine in psychogenic impotence. J Urol 1992, 147:1530–1532.
8. Brindley GS: Pilot experiments on the action of drugs injected into the human corpus cavernosum penis. Br J Pharmacol 1986, 87:405–500.
9. Morales A, Heaton JPW, Carson CC: Andropause: misnomer for true clinical entity. J Urol 2000, 163:705–712. Comprehensive review of current status of hypogonadism and treatment with exogenous androgens. DOI: 10.1016/S0022-5347(05)67788-9
10. Carson CC, Mino RD: Priapism associated with trazodone therapy. J Urol 1988, 139:369–370.
11. Costibile RA, Spevak M: Oral trazodone is not effective therapy for erectile dysfunction: a double blind placebo controlled study. J Urol 1999, 161:1819–1822. This controlled study evaluated traditional therapy for ED using antidepressants and found no evidnece for the trazodone effect. DOI: 10.1016/S0022-5347(05)68813-1
12. Montorsi F, Strambi LF, Guazzoni G, et al.: Effect of yohimbine in psychogenic impotence: a randomized double-blind placebo controlled study. Urology 1994, 44:732–736. DOI: 10.1016/S0090-4295(94)80216-5
13. Susset JG, Tessier CD, Wincaze J, et al.: Effect of yohimbine hydrochloride on erectile impotence: a double-blind study. J Urol 1989, 141:1360–1363.
14. Vogt HJ, Brandall P, Kockott G, et al.: Double-blind placebo controlled safety and efficacy trial with yohimbine hydrochloride in the treatment of non-orgainic erectile dysfunction. Int J Impot Res 1997, 9:155–161. DOI: 10.1038/sj.ijir.3900271
15. Ruck B, Shih RD, Marcus SM: Hypertensive crisis from herbal treatment of impotence. Am J Emerg Med 1999, 17:317–318. DOI: 10.1016/S0735-6757(99)90139-0
16. Tallentire D, McRae G, Spedding M, et al.: Modulation of sexual behavior in the rat by a potent alpha 2 antagonist delequamine (RS15385-197). Br J Pharmacol 1996, 118:63–72.
17. Melman A: L-arginine and penile erection. J Urol 1997, 158:686. DOI: 10.1016/S0022-5347(01)64294-0
18. Zorgniotti AW, Lizza AF: Effective large doses of nitric oxide precusor l-arginine on erectile failure. Int J Impot Res 1994, 6:33–34.
19. Moreland RB, Goldstein I, Traish A: Sildenafil: a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells. Life Sci 1998, 62:309–318. DOI: 10.1016/S0024-3205(98)00158-1
20. Ballard SA, Gingell CJ, Tang K, et al.: Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isoenzymes. J Urol 1998, 159:2164–2171. DOI: 10.1016/S0022-5347(01)63299-3
21. Goldstein I, Lue TF, Padma-Nathan H, et al.: Oral sildenafil and the treatment of erectile dysfunction. N Engl J Med 1998, 338:1397–1404. This study shows the results of pivoted trials of sildenafil in men with ED. An excellent discussion of use, effectiveness, and side effects of first approved PDE5 agent. DOI: 10.1056/NEJM199805143382001
22. Virag R: Indications and early results of sildenafil (Viagra) in erectile dysfunction. Urology 1999, 54:1073–1077. DOI: 10.1016/S0090-4295(99)00310-6
23. Guiliano F, Hultling C, El Masry WS, et al.: Rondomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury. Ann Neurol 1999, 46:15–21. Strong evidence for effectiveness of sildenafil in young men with spinal cord injury of varying levels. Few significant adverse events in this series. DOI: 10.1002/1531-8249(199907)46:1<15::AID-ANA5>3.0.CO;2-U
24. Rendell MS, Rajfer J, Wilson P, et al.: Sildenafil for the treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. JAMA 1999, 281:421–426. DOI: 10.1001/jama.281.5.421
25. Zippe CD, Kedia S, Kedia AW, Pesquealotto F: Sildenafil citrate (Viagra) after radical retropubic prostatectomy. Urology 1999, 54:583–586. A strong statement in favor of nerve sparing prostatectomy in all men to permit sildenafil response postoperatively. The authors found some effect even with unilateral nerve sparing. DOI: 10.1016/S0090-4295(99)00284-8
26. Merrick GS, Butler WM, Lief JH, et al.: Efficacy of sildenafil in prostate brachytherapy patients with erectile dysfunction. Urology 1999, 53:1112–1116. DOI: 10.1016/S0090-4295(99)00048-5
27. Weber DC, Bieri S, Kuntz JM, Miralbell R: Prospective pilot study of sildenafil for treatment of post radiotherapy erectile dysfunction in patients with prostate cancer. J Clin Oncol 1979, 17:3444–3449.
28. Kedia S, Zippe CD, Agarwal A, et al.: Treatment of erectile dysfunction with sildenafil citrate after radiation therapy for prostate cancer. Urology 1999, 54:308–312. DOI: 10.1016/S0090-4295(99)00146-6
29. Kloner RA, Zusman RM: Cardiovascular effects of sildenafil citrate and recommendations for its use. Am J Cardiol 1999, 84:11–17. A useful review and explanation of cardiac effects of sildenafil and sexual activity in men with ED and comorbid conditions. DOI: 10.1016/S0002-9149(99)00114-9
30. Gwinup G: Oral phentolamine in nonspecific erectile insufficiency. Ann Intern Med 1988, 109:162–163.
31. Wagner G, Lacy S, Lewis R: Buccal phentolamine: a pilot trial for male erectile dysfunction at three separate clinics. Int J Impot Res 1994, 6:D78.
32. Heaton JPW, Morales A, Adams MA, et al.: Recovery of erectile function after oral administration of apomorphine. Urology 1995, 45:200–206. DOI: 10.1016/0090-4295(95)80005-0
33. Padman Nathan H, Fromm S, Ruff D, et al.: Efficacy and safety of apomorphine SL vs placebo for male erectile dysfunction. J Urol 1998, 159:241–243.
34. Andersson KE, Gamalmaz H, Waldeck K, et al.: The effect of sildenafil on apomorphine evoked increases in intracavernous pressure in the awake rat. J Urol 1999, 161:1707–1712. Animal experiments that predict a positive additive effect of sildenafil and apomorphine for ED. Combination has advantages over either agent alone. DOI: 10.1016/S0022-5347(05)69009-X
35. Virag R: Intracavernous injection of papaverine for erectile failure. Lancet 1982, 2:938. DOI: 10.1016/S0140-6736(82)90910-2
36. Lee LM, Stevenson RW, Szasz G: Prostaglandin E-1 versus phentolamine-papaverine for the treatment of erectile impotence: a double-blind comparison. J Urol 1989, 141:549–550.
37. Linet OI, Ogring FG: Efficacy in safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 1996, 334:873–877. DOI: 10.1056/NEJM199604043341401
38. Stakl W, Hasun R, Marberger N: Prostaglandin E-1 in the treatment of erectile dysfunction. World J Urol 1990, 8:84–86. DOI: 10.1007/BF01576353
39. McMahon R: A pilot study for the role of intracavernosal injection of vasoactive intestinal polypeptide (VIP) and phentolamine mesylate in the treatment of erectile dysfunction. Int J Impot Res 1996, 8:233–236.
40. Kiely EA, Bloom SR, Williams G: Penile response to intracavernosal vasoactive interstinal polypeptide alone and in combination with other vasoactive agents. Br J Urol 1989, 64:191–194. DOI: 10.1111/j.1464-410X.1989.tb05986.x
41. Gerstenberg TC, Metz T, Ottesen B, Fahrenkrug J: Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure. J Urol 1992, 147:1277–1279.
42. Hermabessiere J, Costa CFP: Efficacy in safety assessment of intracavernous injection of moxisylyte in patients with erectile dysfunction: a double-blind placebo controlled study. Int J Impot Res 1994, 6:D147.
43. Buvat J, Costa P, Moralier D, et al.: Double-blind multicenter study comparing alprostadil alpha cyclodextrin with moxisylyte chlorohydrate in patients with chronic erectile dysfunction. J Urol 1998, 159:116–119. DOI: 10.1016/S0022-5347(01)64030-8
44. Benevides MD, Parivar K, Vick RN, et al.: Intracavernosal injection of a potassium channel opener to treat erectile dysfunction. J Urol 1999, 161(suppl):212. DOI: 10.1097/00005392-199904010-00850
45. Moon DG, Byum HS, Kim JJ: A KATP channel opener as a potential treatment modality for erectile dysfunction. Br J Urol 1999, 83:837–841.
46. Cavalini G: Minoxidil and capsacin: an association of transcutaneous active drugs for erection facilitation. Int J Impot Res 1994, 6:D71.
47. Heaton JPW, Morales A, Owen J, et al.: Topical glycerylternitate causes measurable penile arterial dilation in impotent men. J Urol 1990, 43:729–731.
48. Nunez BD, Andersson DC: Nitroglycerine ointment in the treatment of impotence. J Urol 1993, 150:1241–1243.
49. Cavallini G: Minoxidil versus nitroglycerin: prospective double-blind control trial in transcutaneous erection facilitation for organic impotence. J Urol 1991, 146:50–53.
50. McVary KT, Polepalle S, Riggi S: Topical prostaglandin E1 SEPA gel for the treatment of erectile dysfunction. J Urol 1999, 162:726–731. DOI: 10.1097/00005392-199909010-00025
51. Padma-Nathan H, Hellstrom WJG, Kaiser FE, et al.: Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 1997, 336:1–7. DOI: 10.1056/NEJM199701023360101
52. Porst H: Transurethral alprostadil with MUSE versus intracavernous alprostadil: a comparative study in 103 patients with erectile dysfunction. Int J Impot Res 1997, 9:187–192. DOI: 10.1038/sj.ijir.3900318
53. Fundaram CP, Thomas W, Pryor LE, et al.: Long term follow-up of patients receiving injection therapy for erectile dysfunction. Urology 1997, 49:932–935. DOI: 10.1016/S0090-4295(97)00079-4
54. Heaton JPW, Adams MA, Morales A: Therapeutic taxonomy of treatments for erectile dysfunction: an evolutionary imperative. Int J Impot Res 1997, 9:115–121. This excellent review discusses available treatment options for ED and their effectiveness, as well as a framework for approaching patients with ED. DOI: 10.1038/sj.ijir.3900281